Talphera (NASDAQ:TLPH) said it had reached 75% enrollment in its NEPHRO-CRRT registrational study and remains on track to complete enrollment later in 2026, as the company prepares for a potential commercial launch of its nafamostat anticoagulant candidate for continuous renal replacement therapy, o
Talphera secured $17M in strategic financing to fund operations through its Niyad PMA in late 2026, despite a negative market reaction to its Q3 earnings.
Looking for insights into the US markets one hour before the close of the markets on Tuesday? Delve into the top gainers and losers of today's session and gain valuable market intelligence.
Let's have a look at what is happening on the US markets one hour before the close of the markets on Monday. Below you can find the top gainers and losers in today's session.
Talphera Inc. (TLPH) reported Q2 2025 results with a slight EPS beat but no revenue, aligning with estimates. Stock dipped slightly post-earnings as clinical progress remains key for investor sentiment.
